Dr. Benjamin Zhang is the Chief Medical Officer of JY BioMed and YD Biopharma. He brings deep expertise in cancer immunotherapy, stem cell therapy, and translational medicine. As the inventor of JY’s proprietary gamma delta T cell expansion protocol, he plays a central role in advancing the company’s immunotherapy pipeline. Dr. Zhang oversees clinical development and regulatory strategy, guiding early-stage programs toward safety, compliance, and real-world application. With a background in IND preparation and immune cell engineering, he is a key driver of JY BioMed’s mission to develop innovative, next-generation therapies.

Education

• M.D., School of Medicine, Taipei Medical University

Key skills

• Medical Neuroscience

• Translational Medicine

• Cell Engineering

• Clinical Trial Management

• New Drug Development